Free Trial

Editas Medicine (EDIT) Competitors

Editas Medicine logo
$3.01 +0.01 (+0.33%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$3.00 -0.01 (-0.33%)
As of 09:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EDIT vs. BEAM, CRSP, NTLA, ATAI, CRON, TRVI, RAPP, PHAR, UPB, and SPRY

Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), atai Life Sciences (ATAI), Cronos Group (CRON), Trevi Therapeutics (TRVI), Rapport Therapeutics (RAPP), Pharming Group (PHAR), Upstream Bio (UPB), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

Editas Medicine vs. Its Competitors

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Editas Medicine has a net margin of -608.88% compared to Beam Therapeutics' net margin of -661.31%. Beam Therapeutics' return on equity of -43.15% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-661.31% -43.15% -31.06%
Editas Medicine -608.88%-200.25%-68.57%

Beam Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500.

Beam Therapeutics presently has a consensus target price of $46.40, suggesting a potential upside of 95.53%. Editas Medicine has a consensus target price of $5.10, suggesting a potential upside of 69.44%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
3.08
Editas Medicine
2 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.23

Editas Medicine has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$63.52M37.79-$376.74M-$4.50-5.27
Editas Medicine$32.31M8.38-$237.09M-$2.85-1.06

In the previous week, Beam Therapeutics had 5 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 0 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.42 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Beam Therapeutics Neutral
Editas Medicine Neutral

Summary

Beam Therapeutics beats Editas Medicine on 12 of the 17 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDIT vs. The Competition

MetricEditas MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$269.76M$3.16B$5.76B$10.50B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-1.0621.0476.2526.62
Price / Sales8.38252.06470.4991.77
Price / CashN/A46.3537.4661.85
Price / Book1.859.7813.356.45
Net Income-$237.09M-$52.73M$3.29B$271.57M
7 Day Performance10.66%3.16%1.83%2.55%
1 Month Performance7.50%4.69%3.98%7.22%
1 Year Performance-14.73%16.37%74.39%29.60%

Editas Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDIT
Editas Medicine
3.8677 of 5 stars
$3.01
+0.3%
$5.10
+69.4%
-17.8%$269.76M$32.31M-1.06230High Trading Volume
BEAM
Beam Therapeutics
2.9781 of 5 stars
$22.91
+7.7%
$46.40
+102.5%
-4.0%$2.32B$60.27M-5.09510
CRSP
CRISPR Therapeutics
3.237 of 5 stars
$61.19
+5.8%
$71.60
+17.0%
+30.0%$5.57B$37.31M-11.27460Analyst Forecast
NTLA
Intellia Therapeutics
4.451 of 5 stars
$12.27
+6.1%
$27.11
+121.0%
-20.4%$1.32B$52.86M-2.62600
ATAI
atai Life Sciences
3.2594 of 5 stars
$4.65
flat
$11.25
+141.9%
+367.5%$996.68M$310K-6.7480News Coverage
Analyst Forecast
Gap Up
CRON
Cronos Group
2.5274 of 5 stars
$2.59
+1.6%
N/A+22.8%$991.69M$130.28M51.80450
TRVI
Trevi Therapeutics
1.9668 of 5 stars
$7.96
-1.2%
$21.75
+173.2%
+153.9%$969.35MN/A-18.9520
RAPP
Rapport Therapeutics
3.0565 of 5 stars
$26.19
+5.9%
$35.33
+34.9%
+32.3%$955.88MN/A-10.48N/AHigh Trading Volume
PHAR
Pharming Group
2.0343 of 5 stars
$13.90
+0.1%
$30.00
+115.8%
+92.9%$952.29M$297.20M-106.92280Gap Up
High Trading Volume
UPB
Upstream Bio
1.3991 of 5 stars
$17.35
+3.3%
$56.50
+225.6%
N/A$935.34M$2.37M0.0038
SPRY
ARS Pharmaceuticals
2.7701 of 5 stars
$9.41
-5.5%
$32.50
+245.4%
-29.5%$929.99M$89.15M-19.2090

Related Companies and Tools


This page (NASDAQ:EDIT) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners